Holen Sie sich die Stockscreener-App
12.79
8.58%
-1.20
Handel nachbörslich:
12.79
Schlusskurs vom Vortag:
$13.99
Offen:
$13.19
24-Stunden-Volumen:
1.64M
Relative Volume:
2.62
Marktkapitalisierung:
$770.69M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-214.90M
KGV:
-3.1027
EPS:
-4.1222
Netto-Cashflow:
$-151.25M
1W Leistung:
-28.71%
1M Leistung:
-29.80%
6M Leistung:
-56.12%
1J Leistung:
-63.85%
1-Tages-Spanne:
$12.56
$13.63
1-Wochen-Bereich:
$12.56
$17.68
52-Wochen-Spanne:
$12.56
$40.84
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
12.79 | 770.69M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Biotech Spyre Therapeutics Awards 93,200 Stock Options in Key Talent Push - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week LowHere's Why - MarketBeat
Teacher Retirement System of Texas Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – What’s Next? - Defense World
Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003 - Marketscreener.com
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody - PR Newswire
Game-Changing IL-23 Antibody Enters Clinical Trials: Quarterly Dosing Could Transform Treatment - Stock Titan
Head to Head Contrast: Spyre Therapeutics (NASDAQ:SYRE) & Aptorum Group (NASDAQ:APM) - Defense World
Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Bank of New York Mellon Corp Decreases Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Will Spyre Therapeutics Redefine IBD Treatment With Superior Efficacy And Convenience? - RTTNews
Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Wolfe Research - Defense World
Commit To Buy Spyre Therapeutics At $12.50, Earn 13.5% Annualized Using Options - Nasdaq
Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target -March 18, 2025 at 07:17 am EDT - Marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Arizona State Retirement System - Defense World
Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com
132,200 New Stock Options: Inside Spyre Therapeutics' Latest Employee Compensation Package - StockTitan
Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN
Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News
Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha
Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks
Spyre Therapeutics: Q4 Earnings Snapshot - The Pioneer
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com
Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks
Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks
Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World
Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily
SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com Australia
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat
Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PR Newswire
IBD-Focused Spyre Therapeutics Sets Investor Conference Schedule for MarchWhat to Expect - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):